Notably, the relationship between the BRAF proto-oncogene and MTC pathogenesis has been scarcely described, with only two case reports detecting BRAFV600E mutation in RET-negative MTC tumors, and one study reporting a potentially activating BRAF–PARP12 gene fusion46–48. This evidence concerns the gene PARP12 and medullary thyroid gland carcinoma.